Compare Quantumscape Corp (QS) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quantumscape Corp vs Zimmer Biomet Holdings Inc — how do they compare? Quantumscape Corp trades at $5.57 (market cap $3.72B), while Zimmer Biomet Holdings Inc trades at $88.69 (market cap $17.20B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 4.6× Quantumscape Corp's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Quantumscape Corp pays none. Which is the better fit depends on your goals.
| QS | ZBH | |
|---|---|---|
Market Cap | $3.72B | $17.20B |
Sector | Consumer Cyclical | Health |
52-Week High | $18.44 | $107.71 |
52-Week Low | $5.86 | $79.58 |
Enterprise Value | $2.89B | $24.25B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QuantumScape (QS) trades at $6.05, up 3.24% on the day, amid a bearish technical signal and negative profitability metrics. The company reported a net loss of $435.05 million in 2025, with negative ROE and ROA, while cash flow remains dependent on financing activities. Recent news highlights a joint research agreement with Honda, providing optimism around solid-state battery development, though earnings misses in recent quarters temper near-term expectations.
The outlook remains speculative with high execution risk as QS transitions from R&D to commercialization. Investor sentiment is cautious, reflected in analyst holds and sells, but partnerships like Honda offer long-term potential. Key risks include sustained losses, EV market demand volatility, and manufacturing scalability challenges against established competitors.
Zimmer Biomet (ZBH) trades at $88.92, down 2.41% on the day, with a bearish technical signal but strong fundamentals including a 70.03% gross margin and three consecutive quarterly EPS beats. Revenue grew to $8.23B in 2025, though net income margin compressed to 8.56%. The company announced a $1 billion share repurchase increase and expansion in India, while maintaining a dividend.
The stock offers a 10% upside to the $97.67 consensus price target, supported by value metrics and operational strength, but faces risks from rising debt levels and competitive pressures. Analyst sentiment is mixed with 40% buy ratings, suggesting cautious optimism amid near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
